Oasmia Pharmaceutical AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.01.20	Oasmia to present at Biotech Showcase in San Francisco (GlobeNewswire)
30.12.19	New number of shares and votes in Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
30.12.19	Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019 (GlobeNewswire)
09.12.19	Final result of the rights issue in Oasmia (GlobeNewswire)
06.12.19	Oasmia’s rights issue has been oversubscribed (GlobeNewswire)
27.11.19	Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue (GlobeNewswire)
19.11.19	Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus (GlobeNewswire)
18.11.19	Oasmia invites to investor meetings in connection to the rights issue (GlobeNewswire)
11.11.19	Oasmia resolves on a rights issue of approximately SEK 399 million (GlobeNewswire)
06.11.19	Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019 (GlobeNewswire)
30.10.19	Oasmia recruits Michael of Winklerfelt as new CFO (GlobeNewswire)
14.10.19	Notice of extraordinary general meeting in Oasmia Pharmaceutical AB (GlobeNewswire)
14.10.19	The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million (GlobeNewswire)
26.09.19	Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019 (GlobeNewswire)
26.09.19	Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019 (GlobeNewswire)
18.09.19	Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte (GlobeNewswire)
18.09.19	Oasmia presents Q1 report through audiocast on September 26 (GlobeNewswire)
15.09.19	The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019 (GlobeNewswire)
05.09.19	Oasmia publishes its annual report and adjusts accounts due to write-downs - auditors do not recommend former board to be granted discharge from liability (GlobeNewswire)
04.09.19	Oasmia completes its management team (GlobeNewswire)
28.08.19	Notice of Annual General Meeting in Oasmia Pharmaceutical AB (GlobeNewswire)
27.08.19	Oasmia updates regarding MGC disputes (GlobeNewswire)
23.08.19	Oasmia ADSs delisted from NASDAQ in the US (GlobeNewswire)
20.08.19	Nomination committee in Oasmia for the 2019 AGM (GlobeNewswire)
15.08.19	Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calendar (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Oasmia Pharmaceutical AB

Aktien Top/Flop

Meistgelesene Nachrichten